Table 1. The IC50 of MM, lymphoma, and bortezomib resistant cell lines in each drug.
| Syringolog-1 | Bortezomib | ||||
|---|---|---|---|---|---|
| IC50 | IC50 | IC50 | IC50 | ||
| Cell type | Cell name | (nM) | ratio * | (nM) | ratio * |
| MM | |||||
| U266 | 5.9 | 15 | |||
| RPMI8226 | 6.4 | 20.1 | |||
| KMS-11 | 5.7 | 5.4 | |||
| OPM-2 | 1.3 | 2.8 | |||
| Lymphoma | |||||
| MT-4 | 1.2 | 8.3 | |||
| Hut-78 | 7.6 | 22.5 | |||
| Jurkat | 5.7 | 37.4 | |||
| Btz resistant | |||||
| KMS-11/Btz | 17.4 | 3.1 | 240 | 44.4 | |
| OPM-2/Btz | 5.1 | 3.9 | 293 | 104.6 | |
| MT-4/Btz | 6.4 | 5.3 | 69.5 | 8.4 | |
* Comparison with parental cell line. Btz, bortezomib.
After the incubation with each drug for 72hrs, the IC50 values were determined.